Prognostic Significance Of Circulating Tumour Biomarkers In Patients Treated With Curative-intent Radiotherapy For NSCLC
Funder
National Health and Medical Research Council
Funding Amount
$877,098.00
Summary
More than 50% of cancer patients in Australia receive radiotherapy but many later die from distant metastases. This study of circulating biomarkers (tumour cells and DNA in the bloodstream) builds on evidence from research at Peter Mac showing that some lung cancers might spread during treatment with radiotherapy that would otherwise be curative. This study will help identify cancer patients at high risk of secondary cancers and could allow us to modify treatments to prevent them.
Assessment Of Rectal And Urinary Toxicity From The RADAR Prostate Radiotherapy Trial – Dosimetric Constraints For Novel Symptom Clustering, Derivation Of Radiobiological Parameters And Assessment Of Patient Localisation Effects
Funder
National Health and Medical Research Council
Funding Amount
$323,484.00
Summary
Increasing prostate radiotherapy cure rates by increasing radiation dose is limited by side-effects in the rectum and bladder which can greatly decrease patient quality of life. This study will utilise detailed data, collected during a large Australasian trial, to extract information on how patterns of dose delivery influence side-effects in the bladder and rectum, including a novel definition of rectal toxicity. The result will be more effective future treatment.